Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Diabetes poses a significant risk to bone health, leading to decreased bone mineral density and increased fracture ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

Diabetes significantly increases the risk of bone diseases like osteoporosis, leading to fractures even with normal bone ...

O rthopedic doctors have a bone to pick with all the people who forget they’re carrying a very important skeleton around ...

Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...

The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial.